A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo

The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test new therapies in vivo. Here the authors present a tissue bioengineering strategy for the study of a rare kidney tumor called angiomyolipoma, in vitro and in vivo, using patient...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: J. O. R. Hernandez, X. Wang, M. Vazquez-Segoviano, M. Lopez-Marfil, M. F. Sobral-Reyes, A. Moran-Horowich, M. Sundberg, D. O. Lopez-Cantu, C. K. Probst, G. U. Ruiz-Esparza, K. Giannikou, R. Abdi, E. P. Henske, D. J. Kwiatkowski, M. Sahin, D. R. Lemos
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/928c67a16e704b9e921c20f97413c1e4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test new therapies in vivo. Here the authors present a tissue bioengineering strategy for the study of a rare kidney tumor called angiomyolipoma, in vitro and in vivo, using patient-derived hiPSCs.